Key Points Pfizer can cover its dividends with free cash flow, but doesn't have a huge cushion. The company faces some risks from pipeline setbacks, patent expirations, and U.S. government policies. Its dividend appears to be sustainable despite the uncertainties. 10 stocks we like better than Pfizer › Income investors have liked Pfizer(NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer's 7.6% dividend yield is sustainable? Here's what you need to know.Image source: Getty Images. Looking at the numbers Pfizer's management remains confident about the company's ability to fund the dividend. CFO David Denton emphasized on the first-quarter earnings call that "our commitment to [the] dividend is steadfast." As he has in the past, Denton said that Pfizer intends to maintain and grow the dividend over time. However, I don't think income investors should hang their hats on executives' comments. After all, they aren't definitively promising that the company will continue to pay dividends at current levels. Instead, the more pragmatic approach is to examine its financials to determine how sustainable the dividend is. Pfizer's dividend payout ratio of 122.5% looks concerning at first glance. A company can only pay out more in dividends than it generates in earnings for a limited time. Should income investors be worried? I don't think so. A much better financial metric to consider when evaluating the sustainability of the dividend is free cash flow. Pfizer generated free cash flow of around $9.8 billion in 2024. It paid roughly $9.5 billion in dividends last year. This doesn't give the drugmaker a lot of cushion, but it is producing sufficient free cash flow to cover the dividend payments. Importantly, Pfizer expects to achieve cost savings of $7.2 billion by 2027. This should help boost free cash flow and give more flexibility in funding dividends. Wild cards Does this mean Pfizer's dividend is 100% safe? Unfortunately, no. The company faces several uncertainties that could make it difficult to maintain and grow the dividend. The perennial challenge for drugmakers is the risk of pipeline setbacks. Pfizer recently experienced a highly visible example with safety concerns about danuglipron, which resulted in the company discontinuing development of the experimental weight management pill. Pfizer's financial performance hinges more on its pipeline than some of its peers' do because of multiple patent expirations coming over the next few years. CEO Albert Bourla acknowledged on the Q1 earnings call that the company won't be "a strong top-line growth story for the next three years" due to the loss of exclusivity for several key products. However, he believes Pfizer will be an "EPS [earnings per share] growth story" thanks to its cost reductions, business development, and new product launches. Again, though, Bourla's optimism is warranted only if the pipeline delivers as hoped. Story Continues The steep tariffs threatened by the Trump administration on pharmaceutical imports could also hurt the company. Bourla said on the Q1 call that his discussions with government officials indicated that the main concern is with "critical medicines" made outside the U.S. Also, President Donald Trump recently told pharmaceutical industry leaders that they would have "a lot of time" to move drug manufacturing to the U.S. before being hit by tariffs. While signs point to Pfizer being able to navigate pharmaceutical tariffs relatively well, there's still a financial risk. A potentially greater worry, though, is the White House's plan to implement international reference pricing for some prescription drugs covered by Medicare. This approach, often referred to as "most favored nation" or MFN pricing, pegs the price Medicare pays for drugs to the lowest price paid by other developed countries. How problematic could MFN pricing be for Pfizer? It depends on the details of what the Trump administration does. The good news is that (based on the latest available data) only one of Pfizer's products (pneumococcal vaccine Prevnar 20) ranks in the top 30 drugs for which Medicare Part B spent the most money. The verdict on Pfizer's dividend Considering all these factors, I think Pfizer should be able to continue paying dividends at current levels despite the uncertainties it faces. But I wouldn't bet on the drugmaker's dividend yield remaining as high as it is now. A lot of negativity is baked into Pfizer's share price, with the stock trading at less than 8 times forward earnings. The average forward price-to-earnings ratio of around 16.5 for S&P 500 healthcare stocks is more than twice that. Any pleasant surprises -- perhaps pharmaceutical tariffs that don't hurt Pfizer as much as feared -- could boost the company's share price. If the stock rises, its dividend yield will fall. However, income investors shouldn't focus as much on what the future yield might be as they do on what the dividend payments will be. I predict that over the next few years, Pfizer's dividends will continue to be attractive. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $614,911!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $714,958!* Now, it’s worth notingStock Advisor’s total average return is907% — a market-crushing outperformance compared to163%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know. was originally published by The Motley Fool View Comments
Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...